PRAN: Prana Allowed Key Patent for PBT2 in the United States

[justfishing]

http: //finance.yahoo.com/news/Prana-Allowed-Key-Patent-for-pz-766797119.html?x=0&.v=1

(space between : //)

[Arnold]

Shares of Melbourne-based Prana Biotechnology Ltd. (PRAN) touched a new intraday high of $3.35 on Monday before closing the day's trading at $2.41, making it to the list of top gainers of that day.

A definitive phase IIb trial of PBT2, which will involve 525 patients with mild to moderate Alzheimer's disease, is expected to be commenced before the end of this year. The company is in discussions with potential sources of finance for the upcoming trial, both with investors and pharmaceutical partners.

Pharma Stocks In News - Weekly Roundup